SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Acrivon Reports Third Quarter 2026 Financial Results and Business Highlights

Immunology and inflammation (I&I) established as a second strategic pillar for company which is particularly well-suited for its AP3 precision medicine approachAI-driven AP3 platform was used for profiling against approved JAK inhibitors to identify recently acquired ACR-525, a Phase 2-ready, poten…

ACRV

Related stories